Exosome Uptake Assays

Q: How do you ensure that the fluorescent signal we see is genuinely internalized exosomes and not just dye sticking to the cell surface?

We apply three levels of discrimination. First, parallel incubations at 4°C (which blocks energy-dependent endocytosis) quantify the surface-binding background for subtraction. Second, trypan blue quenching specifically extinguishes extracellular fluorescence while leaving internalized signal intact. Third, confocal Z-stack imaging with orthogonal projections physically demonstrates that signal originates from within the cell volume, not the plasma membrane plane. We report all three metrics in every data package.

Q: What labeling dyes do you use for microbial vesicles, and how do you prevent dye aggregation artifacts?

We select from PKH26, PKH67, DiO, DiI, DiD, and CFSE based on your vesicle membrane composition and downstream detection requirements. Crucially, every labeling reaction is followed by size-exclusion chromatography cleanup to remove unbound dye and dye aggregates. Post-cleanup NTA verification confirms that the labeled preparation contains predominantly single vesicles rather than dye aggregates.

Q: Can you distinguish between different internalization pathways (clathrin, caveolin, macropinocytosis)?

Yes. Our standard inhibitor panel includes chlorpromazine (clathrin-mediated endocytosis), genistein (caveolae-mediated uptake), amiloride or EIPA (macropinocytosis), and dynasore (dynamin-dependent pathways as a convergent control). Each inhibitor is titrated to its validated selective concentration range, and cells are pre-incubated before mEV addition. For genetic-level confirmation, we offer siRNA-mediated knockdown of clathrin heavy chain, caveolin-1, or Pak1 with uptake quantification in knockdown vs. scrambled control cells.

Q: What cell types can you use for uptake assays?

We routinely work with epithelial cell lines (Caco-2, HeLa, A549), immune cells (RAW 264.7 macrophages, THP-1 monocytes, primary dendritic cells), fibroblasts, endothelial cells, and cancer cell lines from multiple tissue origins. Client-provided cell lines are accepted after mycoplasma testing and growth characterization. For microbial vesicle uptake relevant to food or probiotic applications, intestinal epithelial models are our most frequently requested format.

Q: How do microbial vesicle uptake assays differ from mammalian exosome uptake assays?

Microbial vesicles present distinct challenges. OMVs carry LPS and other pathogen-associated molecular patterns that can trigger receptor-mediated uptake pathways not engaged by mammalian exosomes. Gram-positive CMVs have different surface adhesion properties due to LTA. Microbial vesicles also tend to be more heterogeneous in size and more prone to aggregation. Our protocols are specifically optimized for these properties, including detergent-free labeling conditions that preserve OMV surface antigens and size-exclusion cleanup steps validated for microbial vesicle size distributions.

Q: Can you integrate uptake data with functional readouts like reporter gene delivery or cytokine induction?

Absolutely. Uptake assays are often the first step in a broader functional characterization cascade. We routinely design integrated studies where uptake quantification is paired with reporter gene delivery assays to confirm functional cargo transfer, or with multiplex cytokine profiling to correlate internalization kinetics with immunomodulatory responses. This closed-loop approach—from uptake to function—provides the strongest mechanistic evidence for your mEV activity.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

Whether an exosome docks, fuses, or gets internalized by a target cell determines everything about its functional fate—yet reliably distinguishing genuine vesicle uptake from surface adhesion or dye artifact remains a persistent challenge. At Creative BioMart Microbe, we provide quantitative exosome uptake assays purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived cytoplasmic membrane vesicles (CMVs), and fungal exosomes. Our platform combines multiple orthogonal detection modalities—fluorescence microscopy, flow cytometry, and high-content imaging—to deliver uptake kinetics, internalization pathway identification, and intracellular trafficking data with the rigor required for publication and regulatory submission.

Unlike generic mammalian EV services that apply the same labeling and detection protocols regardless of vesicle origin, our microbial-native workflows account for the unique lipopolysaccharide (LPS) and lipoteichoic acid (LTA) surface chemistry, size heterogeneity, and aggregation tendencies of mEVs. From PKH dye optimization to confocal co-localization with organelle markers, each assay is designed to minimize the dye aggregation artifacts and false-positive signals identified in the recent EV methodology literature. The result is uptake data you can trust—quantitative internalization rates, time-course kinetics, and mechanistic insight into whether your mEVs enter via clathrin-mediated endocytosis, macropinocytosis, or membrane fusion. Contact us to discuss your exosome uptake study requirements.

Multi-stage scientific workflow diagram illustrating the exosome uptake assay process from mEV labeling and characterization through co-incubation with target cells to multi-modal detection by confocal microscopy, flow cytometry, and high-content imaging, culminating in quantitative uptake report delivery.
Figure 1. Exosome uptake assay workflow spanning fluorescent labeling, cell co-incubation, multi-modal detection, and quantitative data reporting for microbial extracellular vesicles.

Services

Service Workflow

Our exosome uptake assay workflow follows a structured sequence from labeling optimization to quantitative data delivery. Each step is customized based on your vesicle type, target cell line, and research question.

Six-step horizontal workflow showing Query & Configure, Fluorescent Labeling Optimization, Co-Incubation Setup, Multi-Modal Detection, Quantitative Image & Flow Analysis, and Data Report Delivery.

Inquiry

Service Details

3D illustration of fluorescently labeled exosomes with PKH26 and PKH67 dye molecules embedding into vesicle membranes, shown alongside a size-exclusion chromatography column removing unbound dye.

Fluorescent Labeling & Dye Optimization

We develop optimized labeling protocols for each mEV type, selecting from PKH, Di-series, and CFSE dyes based on vesicle membrane composition and experimental requirements. Post-labeling cleanup by size-exclusion chromatography removes dye aggregates that cause false-positive signals. Labeling efficiency and vesicle integrity are verified by NTA and TEM before downstream assays.

3D illustration showing a confocal microscope objective focused on cultured cells with internalized fluorescent exosomes visible as punctate dots within the cytoplasm, with organelle co-localization markers shown in separate color channels.

Confocal Microscopy & Co-Localization Analysis

High-resolution confocal imaging captures spatial and temporal patterns of mEV internalization. We perform multi-channel acquisition with organelle markers (Lysotracker, ER-Tracker, MitoTracker) to map intracellular trafficking routes. Quantitative co-localization analysis using Pearson and Manders coefficients distinguishes membrane-bound from truly internalized vesicles.

3D illustration of a flow cytometry system with laser beams interrogating fluorescently labeled cells in a stream, showing histogram overlay comparing untreated control vs exosome-treated cell populations with fluorescence shift.

Flow Cytometry-Based Uptake Quantification

We measure the percentage of fluorescent-positive cells and mean fluorescence intensity (MFI) following mEV co-incubation. Time-course experiments at 0.5, 1, 2, 4, 8, and 24 hours generate uptake kinetics curves. Inhibition studies with chemical blockers (chlorpromazine, genistein, amiloride) identify the dominant internalization pathway for your vesicles.

3D illustration of a high-content screening platform with automated microscopy capturing multi-well plate images, overlaid with cell segmentation masks and quantitative readout heatmaps showing per-cell uptake intensity.

High-Content Screening for Parallel Uptake Analysis

Our high-content imaging platform enables simultaneous evaluation of mEV uptake across multiple conditions—different doses, time points, cell types, or inhibitor treatments—in a single 96- or 384-well experiment. Automated image segmentation quantifies per-cell internalization with single-vesicle resolution, generating statistically robust datasets.

3D illustration showing a schematic of endocytosis pathways with chemical inhibitors docked at clathrin, caveolin, and macropinocytosis entry points, with bar charts comparing uptake reduction under each inhibitor condition.

Internalization Pathway Deconvolution

Using a panel of pharmacological inhibitors and temperature-controlled experiments, we determine whether your mEVs enter via clathrin-mediated endocytosis, caveolae-mediated uptake, macropinocytosis, or direct membrane fusion. For advanced studies, siRNA knockdown of pathway-specific genes provides genetic-level confirmation of the internalization mechanism.

3D illustration of a comprehensive data report with uptake kinetics graphs, confocal image panels, flow cytometry histograms, and statistical analysis tables, with a certification seal in the corner.

Quantitative Data Analysis & Reporting

Every uptake assay delivers a complete data package: confocal image stacks with co-localization quantification, flow cytometry FCS files with gating strategy, uptake kinetics curves with calculated rate constants, and statistical comparisons across conditions. Publication-ready figures and methods sections are provided to accelerate manuscript preparation.

Service Specifications & QC Standards

Instrumentation & Capability

Confocal microscopy: Laser scanning confocal with spectral unmixing for multi-channel co-localization.
Flow cytometry: High-sensitivity cytometers with small-particle detection gates calibrated for 100–1000 nm vesicles.
High-content screening: Automated spinning-disk confocal with environmental control for live-cell imaging.
NTA/DLS: Nanoparticle tracking and dynamic light scattering for pre- and post-labeling vesicle integrity.
TEM: Negative-stain TEM for morphological verification of labeled vesicle preparations.
Image analysis: Automated segmentation and co-localization pipelines.

Typical Data Range

Uptake-positive cell population: 15–95% (dose and time dependent).
Detection sensitivity: Fluorescent signal above autofluorescence at ≥0.5 μg/mL mEV protein.
Time-course resolution: 0.5, 1, 2, 4, 8, 24 h standard panel (custom intervals available).
Co-localization precision: Manders coefficient quantification with ≤0.05 threshold discrimination.
Flow cytometry CV: <10% intra-assay, <15% inter-assay for MFI measurements.
High-content throughput: Up to 384 conditions per imaging run.
Inhibitor panel coverage: Clathrin, caveolin, macropinocytosis, and dynamin targets as standard.

Turnaround Time

Project Type	Timeline
Labeling optimization (per mEV type)	1–2 weeks
Single time-point uptake assay (confocal + flow)	1–2 weeks
Full time-course kinetics (6 time points, 2 modalities)	2–3 weeks
Internalization pathway deconvolution (inhibitor panel)	2–3 weeks
High-content multi-condition screening	2–4 weeks
Comprehensive uptake characterization package	4–6 weeks

Timelines may vary based on cell type, mEV availability, and experimental complexity.

Deliverables

Labeling optimization report: Dye selection rationale, protocol, pre- and post-labeling QC data.
Confocal image dataset: Raw multi-channel Z-stacks and maximum intensity projections.
Flow cytometry data: FCS files with gating strategy and population statistics.
Co-localization analysis: Pearson and Manders coefficients with statistical confidence intervals.
Uptake kinetics report: Time-course curves, rate constants, and plateau analysis.
Pathway identification report: Inhibitor response profiles with IC₅₀ values where applicable.
Publication-ready figures: Processed images, graphs, and statistical summaries formatted to journal specifications.

Quality Control

Pre-assay vesicle QC: NTA size distribution, protein concentration, and TEM morphology on every batch.
Dye aggregate control: SEC post-labeling cleanup verified by NTA for every labeling preparation.
No-vesicle dye control: Parallel dye-only samples to quantify non-specific signal background.
Temperature control: 4°C parallel incubations to distinguish energy-dependent uptake from passive adsorption.
Trypan blue quenching: Cell surface fluorescence quenching to separate internalized from membrane-bound signal.
Positive controls: Transferrin-AlexaFluor conjugates for endocytosis pathway validation.
Intra-assay CV ≤10%; inter-assay CV ≤15% for all quantitative endpoints.
MISEV2023-aligned reporting: Minimal information checklist compliance for all uptake study documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
mEV source (microbial species, strain designation) Target cell type and culture conditions Labeling compatibility requirements (live vs. fixed cell imaging) Preferred detection modality (confocal, flow, high-content) Number of experimental conditions (time points, doses, inhibitors) Prior characterization data (NTA, TEM, protein concentration)	Hypothesized uptake mechanism for targeted inhibitor selection Specific organelle markers for co-localization studies Custom antibody panels for flow cytometry phenotyping Desired statistical power and replicate requirements Publication target journal for figure formatting	Uncharacterized vesicle preparations (no size or concentration data) Aggregated or degraded vesicle samples Samples with unknown storage history or freeze-thaw cycles Crude culture supernatants without enrichment Samples shipped at ambient temperature without cold-chain documentation Vesicles from pathogenic BSL-3 organisms without prior biosafety review

Recommended Sample Quantity by Assay:

Assay Type	Minimum	Recommended
Labeling optimization	50 μg total protein	100–200 μg total protein
Single time-point confocal (per condition)	5 μg total protein	10–20 μg total protein
Flow cytometry uptake (per condition)	2 μg total protein	5–10 μg total protein
Full time-course kinetics (6 time points)	30 μg total protein	60–100 μg total protein
Inhibitor pathway panel (per panel)	20 μg total protein	40–60 μg total protein
High-content multi-condition screening	50 μg total protein	100–200 μg total protein

Storage & Shipping: Ship purified mEV suspensions in sterile PBS on dry ice with cold-chain documentation. Include certificate of analysis or prior characterization data (NTA size/concentration, protein content, TEM images if available). Record the number of freeze-thaw cycles. For live-cell imaging projects, provide target cell line information and culture protocols in advance for cell line establishment and validation. Microbial Exosome Services isolation and characterization are available upstream if starting from microbial culture.

Inquiry

Our Advantages

Microbial Vesicle-Specific Labeling Protocols — Optimized labeling for each mEV type with mandatory SEC cleanup eliminates dye aggregate false positives validated by NTA.
Multi-Modal Orthogonal Detection — Every study combines confocal microscopy and flow cytometry for spatial resolution and population quantification with cross-validation.
Internalization vs. Surface Binding Discrimination — Temperature controls, trypan blue quenching, and pH probes distinguish genuine internalization from surface adsorption.
Pathway Deconvolution Beyond Generic Inhibition — Titrated inhibitor panels plus siRNA knockdown of clathrin, caveolin-1, and Pak1 confirm genetic-level pathway involvement.
MISEV2023-Compliant Reporting — All studies follow MISEV2023 guidelines with detailed protocols, control results, and raw data for peer review.

Applications

3D icon showing a vesicle carrying therapeutic cargo molecules approaching and entering a target cell, with the cargo releasing into the cytoplasm.

Drug Delivery Vector Validation

Quantify mEV uptake efficiency in target vs. off-target cell types to validate delivery specificity and inform dosing strategies.

3D icon of an immune cell with surface receptors capturing a microbial vesicle, showing internalization and downstream signaling cascade activation.

Immunomodulation Mechanism Studies

Determine how OMV or probiotic mEV uptake by macrophages, dendritic cells, or T cells triggers innate and adaptive immune responses.

3D icon showing an intestinal epithelial monolayer with tight junctions, with microbial vesicles crossing the barrier via transcytosis and being tracked by fluorescence.

Barrier & Transcytosis Studies

Assess mEV transport across intestinal, airway, or blood-brain barrier models, essential for food-grade and therapeutic vesicle development.

3D icon showing a comparison matrix with multiple bacterial strains producing vesicles, with bar charts ranking their relative uptake efficiency in target cells.

Strain & Engineering Benchmarking

Compare uptake efficiency across wild-type vs. engineered mEV variants or across different microbial strains to select optimal production candidates.

Case Study

Case Study 1: Low Efficiency of Common Fluorescent Dyes in Labeling Extracellular Vesicles

Researchers systematically evaluated two commonly used fluorescent dyes—PKH26 and C5-maleimide-Alexa633—for labeling extracellular vesicles (EVs) in uptake studies. Using mEmerald-CD81-expressing MCF7-derived EVs as a reference standard, they applied rank-weighted co-localization (RWC) algorithms to quantify the proportion of genuine EVs that were successfully dual-labeled. Strikingly, only 3.9% of EVs overlapped with the maleimide signal, and only 4.8% of mEmerald-CD81 signals overlapped with PKH26. Even under serum-free conditions, PKH26 labeling improved to only 11.0%. Critically, both dyes formed contaminating nanoparticle aggregates detectable by nanoparticle tracking analysis (NTA) in cell-free PBS controls. Cellular uptake experiments in HeLa cells further revealed that maleimide and mEmerald-CD81 signals occupied non-overlapping subcellular compartments, confirming that most dye signal was unrelated to genuine EV internalization.

Confocal microscopy images of HeLa cells treated with maleimide C5 AF633 or PKH26 dual-stained mEmerald-CD81 EVs showing uptake patterns and subcellular distribution after 3 hours.
Figure 2. Uptake of dual stained mEmerald-CD81 EVs. Representative confocal images of HeLa cells treated with maleimide C5 AF633 or PKH26 dual stained EVs. (Melling, et al. 2022)

Case Study 2: Live-Cell Reporter Reveals Exosome Uptake Kinetics and Intracellular Fate

Sung et al. developed an improved pH-sensitive exosome reporter, pHluo_M153R-CD63, containing a single M153R stabilizing mutation that dramatically increased brightness and enabled stable cell line generation. Immunogold TEM confirmed specific labeling of small EVs (105–135 nm peak diameter), while Rab27a knockdown validation demonstrated that the reporter faithfully tracked genuine exosome secretion. Using a dual-color pHluo_M153R-CD63-mScarlet construct, the team tracked the complete exosome life cycle including MVB trafficking, plasma membrane fusion, and recipient cell uptake. Time-lapse imaging of HT1080 cells revealed a median internalization time of 6 minutes from initial filopodial contact to endocytosis, followed by a median endosomal acidification time of 7 minutes. In vivo tracking in chick embryo models demonstrated a plasma half-life of approximately 15 minutes for circulating exosomes, providing the first dynamic quantification of exosome clearance kinetics.

Live confocal time-lapse microscopy of HT1080 cells showing filopodial contact with exosome deposits and subsequent endosome acidification, visualized by pHluo_M153R-CD63 green and CD63-mScarlet magenta dual-color reporter.
Figure 3. Dual reporter reveals MVB transport before fusion and endosome acidification after uptake. Time-lapse imaging of exosome internalization showing filopodial contact and endosomal acidification in HT1080 cells. (Sung, et al. 2020)

FAQs

Q: How do you ensure that the fluorescent signal we see is genuinely internalized exosomes and not just dye sticking to the cell surface?

A: We apply three levels of discrimination. First, parallel incubations at 4°C (which blocks energy-dependent endocytosis) quantify the surface-binding background for subtraction. Second, trypan blue quenching specifically extinguishes extracellular fluorescence while leaving internalized signal intact. Third, confocal Z-stack imaging with orthogonal projections physically demonstrates that signal originates from within the cell volume, not the plasma membrane plane. We report all three metrics in every data package.

Q: What labeling dyes do you use for microbial vesicles, and how do you prevent dye aggregation artifacts?

A: We select from PKH26, PKH67, DiO, DiI, DiD, and CFSE based on your vesicle membrane composition and downstream detection requirements. Crucially, every labeling reaction is followed by size-exclusion chromatography cleanup to remove unbound dye and dye aggregates. Post-cleanup NTA verification confirms that the labeled preparation contains predominantly single vesicles rather than dye aggregates.

Q: Can you distinguish between different internalization pathways (clathrin, caveolin, macropinocytosis)?

A: Yes. Our standard inhibitor panel includes chlorpromazine (clathrin-mediated endocytosis), genistein (caveolae-mediated uptake), amiloride or EIPA (macropinocytosis), and dynasore (dynamin-dependent pathways as a convergent control). Each inhibitor is titrated to its validated selective concentration range, and cells are pre-incubated before mEV addition. For genetic-level confirmation, we offer siRNA-mediated knockdown of clathrin heavy chain, caveolin-1, or Pak1 with uptake quantification in knockdown vs. scrambled control cells.

Q: What cell types can you use for uptake assays?

A: We routinely work with epithelial cell lines (Caco-2, HeLa, A549), immune cells (RAW 264.7 macrophages, THP-1 monocytes, primary dendritic cells), fibroblasts, endothelial cells, and cancer cell lines from multiple tissue origins. Client-provided cell lines are accepted after mycoplasma testing and growth characterization. For microbial vesicle uptake relevant to food or probiotic applications, intestinal epithelial models are our most frequently requested format.

Q: How do microbial vesicle uptake assays differ from mammalian exosome uptake assays?

A: Microbial vesicles present distinct challenges. OMVs carry LPS and other pathogen-associated molecular patterns that can trigger receptor-mediated uptake pathways not engaged by mammalian exosomes. Gram-positive CMVs have different surface adhesion properties due to LTA. Microbial vesicles also tend to be more heterogeneous in size and more prone to aggregation. Our protocols are specifically optimized for these properties, including detergent-free labeling conditions that preserve OMV surface antigens and size-exclusion cleanup steps validated for microbial vesicle size distributions.

Q: Can you integrate uptake data with functional readouts like reporter gene delivery or cytokine induction?

A: Absolutely. Uptake assays are often the first step in a broader functional characterization cascade. We routinely design integrated studies where uptake quantification is paired with reporter gene delivery assays to confirm functional cargo transfer, or with multiplex cytokine profiling to correlate internalization kinetics with immunomodulatory responses. This closed-loop approach—from uptake to function—provides the strongest mechanistic evidence for your mEV activity.

References:

Melling, G. E., et al. (2022). Confocal microscopy analysis reveals that only a small proportion of extracellular vesicles are successfully labelled with commonly utilised staining methods. Scientific Reports, 12, 262.
Sung, B. H., et al. (2020). A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nature Communications, 11, 2092.

Services

Inquiry